AAAAAA

   
Results: 1-25 | 26-36
Results: 1-25/36
New indications for thalidomide
Authors: Tuinmann, G Hegewisch-Becker, S Hossfeld, DK
Citation: G. Tuinmann et al., New indications for thalidomide, DEUT MED WO, 126(42), 2001, pp. 1178-1182
High-dosage treatment of breast cancer - against
Authors: Hossfeld, DK
Citation: Dk. Hossfeld, High-dosage treatment of breast cancer - against, DEUT MED WO, 126(39), 2001, pp. 1092-1092
A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients withadvanced colorectal cancer
Authors: Fiedler, W Kruger, W Laack, E Mende, T Vohwinkel, G Hossfeld, DK
Citation: W. Fiedler et al., A clinical trial of edrecolomab, interleukin-2 and GM-CSF in patients withadvanced colorectal cancer, ONCOL REP, 8(2), 2001, pp. 225-231
Cancer on the threshold of a new millenium - Introduction
Authors: Hossfeld, DK
Citation: Dk. Hossfeld, Cancer on the threshold of a new millenium - Introduction, EUR J CANC, 37, 2001, pp. S3-S3
The European Cancer Conference Lisbon, 21-25 October 2001 - Introduction
Authors: Wagener, DJT Hossfeld, DK
Citation: Djt. Wagener et Dk. Hossfeld, The European Cancer Conference Lisbon, 21-25 October 2001 - Introduction, EUR J CANC, 37, 2001, pp. IX-IX
Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial
Authors: Laack, E Mende, T Benk, J Chemaissani, A Scholtze, J Lorenz, C Niestroy, A Dalhoff, K Muller, T Walter, T Durk, H Edler, L Hossfeld, DK
Citation: E. Laack et al., Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial, EUR J CANC, 37(5), 2001, pp. 583-590
Necrotizing glomerulonephritis associated with Hodgkin's disease
Authors: Wolf, G Krenz, I Hegewisch-Becker, S Hossfeld, DK Helmchen, U Stahl, RAK
Citation: G. Wolf et al., Necrotizing glomerulonephritis associated with Hodgkin's disease, NEPH DIAL T, 16(1), 2001, pp. 187-188
(18)FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma
Authors: de Wit, M Bohuslavizki, KH Buchert, R Bumann, D Clausen, M Hossfeld, DK
Citation: M. De Wit et al., (18)FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma, ANN ONCOL, 12(1), 2001, pp. 29-37
Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrow
Authors: Duhrsen, U Martinez, T Vohwinkel, G Ergun, S Sun, L McMahon, G Durig, J Hossfeld, DK Fielder, W
Citation: U. Duhrsen et al., Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrow, GROW FACTOR, 19(1), 2001, pp. 1-17
Chromosomal gains and losses are uncommon in hairy cell leukemia: a study based on comparative genomic hybridization and interphase fluorescence in situ hybridization
Authors: Dierlamm, J Stefanova, M Wlodarska, I Michaux, L Hinz, K Penas, EMM Maes, B Hagemeijer, A De Wolf-Peeters, C Hossfeld, DK
Citation: J. Dierlamm et al., Chromosomal gains and losses are uncommon in hairy cell leukemia: a study based on comparative genomic hybridization and interphase fluorescence in situ hybridization, CANC GENET, 128(2), 2001, pp. 164-167
Implantable device for intravenous drug delivery in the rat
Authors: de Wit, M Raabe, A Tuinmann, G Hossfeld, DK
Citation: M. De Wit et al., Implantable device for intravenous drug delivery in the rat, LAB ANIMALS, 35(4), 2001, pp. 321-324
ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas
Authors: Hanel, M Kroger, N Hoffknecht, MM Peters, SO Metzner, B Fiedler, F Braumann, D Schubert, JC Illiger, HJ Hanel, A Kruger, WH Zeller, W Weh, HJ Hossfeld, DK Zander, AR
Citation: M. Hanel et al., ASHAP - an effective salvage therapy for recurrent and refractory malignant lymphomas, ANN HEMATOL, 79(6), 2000, pp. 304-311
Chronic lymphocytic leukaemia: risk-adapted therapy
Authors: Hossfeld, DK
Citation: Dk. Hossfeld, Chronic lymphocytic leukaemia: risk-adapted therapy, ANN ONCOL, 11, 2000, pp. 197-198
Mitoxantrone-related acute myelocytic leukemias
Authors: Hossfeld, DK
Citation: Dk. Hossfeld, Mitoxantrone-related acute myelocytic leukemias, ANN ONCOL, 11(10), 2000, pp. 1215-1216
UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectalcancer
Authors: Schilling, G Lipp, R Hegewisch-Becker, S Hossfeld, DK
Citation: G. Schilling et al., UFT/leucovorin plus weekly irinotecan in advanced or metastatic colorectalcancer, ONCOLOGY-NY, 14(10), 2000, pp. 38-40
Irinotecan (Campto((R))) - Clinical overview - Editorial
Authors: Hossfeld, DK
Citation: Dk. Hossfeld, Irinotecan (Campto((R))) - Clinical overview - Editorial, ONKOLOGIE, 23, 2000, pp. S1-S1
Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer
Authors: Kroger, N Kleeberg, UR Mross, K Edler, L Sass, G Hossfeld, DK
Citation: N. Kroger et al., Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer, ONKOLOGIE, 23(1), 2000, pp. 60-62
Genetic abnormalities in marginal zone B-cell lymphoma
Authors: Dierlamm, J Wlodarska, I Michaux, L Stefanova, M Hinz, K Van den Berghe, H Hagemeijer, A Hossfeld, DK
Citation: J. Dierlamm et al., Genetic abnormalities in marginal zone B-cell lymphoma, HEMATOL ONC, 18(1), 2000, pp. 1-13
Polysomy 13 with concomitant deletion of 13q13-14 involving the retinoblastoma gene and the D13S25 locus in a case of acute myeloid leukemia
Authors: Stefanova, M Dierlamm, J Michaux, L Leberecht, P Seeger, D Hinz, K Hossfeld, DK
Citation: M. Stefanova et al., Polysomy 13 with concomitant deletion of 13q13-14 involving the retinoblastoma gene and the D13S25 locus in a case of acute myeloid leukemia, CANC GENET, 119(2), 2000, pp. 158-161
Derivation of a new hematopoietic cell line with endothelial features froma patient with transformed myeloproliferative syndrome - A case report - Author reply
Authors: Fiedler, W Gehling, U Hossfeld, DK
Citation: W. Fiedler et al., Derivation of a new hematopoietic cell line with endothelial features froma patient with transformed myeloproliferative syndrome - A case report - Author reply, CANCER, 89(1), 2000, pp. 222-223
Derivation of a new hematopoietic cell line with endothelial features froma patient with transformed myeloproliferative syndrome - A case report
Authors: Fiedler, W Henke, RP Ergun, S Schumacher, U Gehling, UM Vohwinkel, G Kilic, N Hossfeld, DK
Citation: W. Fiedler et al., Derivation of a new hematopoietic cell line with endothelial features froma patient with transformed myeloproliferative syndrome - A case report, CANCER, 88(2), 2000, pp. 344-351
Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes
Authors: Dierlamm, J Baens, M Stefanova-Ouzounova, M Hinz, K Wlodarska, I Maes, B Steyls, A Driessen, A Verhoef, G Gaulard, P Hagemeijer, A Hossfeld, DK De Wof-Peeters, C Marynen, P
Citation: J. Dierlamm et al., Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT specific probes, BLOOD, 96(6), 2000, pp. 2215-2218
In vitro differentiation of endothelial cells from AC133-positive progenitor cells
Authors: Gehling, UM Ergun, S Schumacher, U Wagener, C Pantel, K Otte, M Schuch, G Schafhausen, P Mende, T Kilic, N Kluge, K Schafer, B Hossfeld, DK Fiedler, W
Citation: Um. Gehling et al., In vitro differentiation of endothelial cells from AC133-positive progenitor cells, BLOOD, 95(10), 2000, pp. 3106-3112
Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34(+) cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34(+) cells
Authors: Zeller, W Kroger, N Berger, J Krueger, W Dierlamm, J Stockschlader, M Gutensohn, K Hossfeld, DK Zander, AR
Citation: W. Zeller et al., Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34(+) cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34(+) cells, J HEMATH ST, 8(5), 1999, pp. 539-546
Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas
Authors: Rummel, MJ Chow, KU Jager, E Leimer, L Hossfeld, DK Bergmann, L Peters, HD Hansmann, ML Meyer, A Hoelzer, D Mitrou, PS
Citation: Mj. Rummel et al., Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas, LEUK LYMPH, 35(1-2), 1999, pp. 129-138
Risultati: 1-25 | 26-36